Evidence map›Paper›PMID 39944822›Full record

ReviewFrontiers in oncology2025

Carcinogenic and anticancer activities of microbiota-derived secondary bile acids.

Mobina Kouhzad, Friedrich Götz, Tahereh Navidifar, Elahe Taki, Mahsa Ghamari, Roghayeh Mohammadzadeh, Maryam Seyedolmohadesin, Narjess Bostanghadiri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mobina KouhzadDepartment of Genetics, Faculty of Science, Islamic Azad University North Tehran Branch, Tehran, Iran.
Friedrich GötzDepartment of Microbial Genetics, Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT), University of Tübingen, Tübingen, Germany.
Tahereh NavidifarDepartment of Basic Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.
Elahe TakiDepartment of Microbiology, School of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran.
Mahsa GhamariDepartment of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Roghayeh MohammadzadehDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam SeyedolmohadesinDepartment of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Azad University, Tehran, Iran.
Narjess BostanghadiriResearch Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary bile acids (SBAs), which are metabolites produced by gut microbiota, have been implicated in both carcinogenic and anticancer processes. This review explores the dual role of SBAs, focusing on their molecular mechanisms and biological effects. The carcinogenic activities of SBAs include DNA damage, promotion of oxidative stress, and modulation of signaling pathways that drive tumorigenesis. Conversely, some SBAs exhibit anticancer properties by inducing apoptosis, inhibiting cell proliferation, and modulating immune responses. The article also discusses the complex interplay between SBAs and the host's genetic and environmental factors, highlighting potential therapeutic implications and the need for targeted strategies to mitigate risks while harnessing beneficial effects. A comprehensive understanding of the delicate equilibrium between the deleterious and salutary impacts of SBAs has the potential to facilitate the development of innovative cancer prevention and treatment methodologies.

Indexed as

anticancerbile acidscarcinogenicmicrobiotasecondary bile acids

Identifiers

PMID39944822
PMCPMC11813773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.